分组1 - Zeta Global Holdings reported quarterly earnings of $0.28 per share, exceeding the Zacks Consensus Estimate of $0.23 per share, and showing an increase from $0.20 per share a year ago, resulting in an earnings surprise of +23.51% [1] - The company achieved revenues of $394.64 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 3.73%, and up from $314.67 million year-over-year [2] - Zeta has outperformed consensus revenue estimates four times over the last four quarters, while it has surpassed consensus EPS estimates two times [2] 分组2 - The stock has underperformed the market, losing about 26.4% since the beginning of the year, compared to a decline of 0.1% for the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.12 on revenues of $362.02 million, and for the current fiscal year, it is $0.99 on revenues of $1.73 billion [7] 分组3 - The Zacks Industry Rank indicates that the Technology Services sector is currently in the bottom 38% of over 250 Zacks industries, suggesting potential challenges for stocks in this sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]

Core Insights - The health care sector is experiencing a trend of oversold stocks, presenting potential buying opportunities for undervalued companies [1][2] Group 1: Oversold Stocks - Inotiv Inc (NASDAQ:NOTV) has an RSI of 26.7, with shares falling 33.2% to close at $0.69. The company anticipates fourth-quarter revenue between $137.5 million and $138.5 million, a 60% increase year-over-year in its Discovery and Safety Assessment services [3][8] - Airsculpt Technologies Inc (NASDAQ:AIRS) has an RSI of 29.3, with shares declining 23.8% to close at $4.17. The company reported lower-than-expected third-quarter results and reduced its FY25 revenue outlook, with a 60% drop in stock price over the past month [4][8] - Neuronetics Inc (NASDAQ:STIM) has an RSI of 23.9, with shares falling 17.1% to close at $1.65. The company cut its FY2025 sales guidance, experiencing a 40% decline in stock price over the past month [5][8]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Motorsport Games Inc. (MSGM) has seen a substantial increase of 122%, trading at $4.88 [3] - Globus Medical, Inc. (GMED) is up 27%, currently priced at $78.75 [3] - JFrog Ltd. (FROG) has risen by 26%, trading at $59.60 [3] - FIGS, Inc. (FIGS) is up 19%, with a trading price of $8.97 [3] - Organogenesis Holdings Inc. (ORGO) has increased by 18%, trading at $4.59 [3] - PureCycle Technologies, Inc. (PCT) is up 17%, currently priced at $11.31 [3] - Expedia Group, Inc. (EXPE) has risen by 16%, trading at $255.10 [3] - 10x Genomics, Inc. (TXG) is up 13%, currently priced at $14.72 [3] - Abacus Global Management, Inc. (ABL) has increased by 12%, trading at $5.95 [3] - GigaCloud Technology Inc. (GCT) is up 9%, currently priced at $27.80 [3] Premarket Losers - Davis Commodities Limited (DTCK) has experienced a significant decline of 65%, trading at $2.23 [4] - Eledon Pharmaceuticals, Inc. (ELDN) is down 46%, currently priced at $2.19 [4] - Treace Medical Concepts, Inc. (TMCI) has decreased by 35%, trading at $4.00 [4] - Energys Group Limited (ENGS) is down 30%, currently priced at $2.77 [4] - Intellia Therapeutics, Inc. (NTLA) has seen a decline of 27%, trading at $8.89 [4] - Fox Factory Holding Corp. (FOXF) is down 24%, currently priced at $16.60 [4] - Opendoor Technologies Inc. (OPEN) has decreased by 24%, trading at $4.94 [4] - AirSculpt Technologies, Inc. (AIRS) is down 21%, currently priced at $8.27 [4] - Power Solutions International, Inc. (PSIX) has seen a decline of 20%, trading at $64.25 [4] - ClearPoint Neuro, Inc. (CLPT) is down 17%, currently priced at $15.00 [4]

Core Insights - U.S. stock futures are lower, with Nasdaq futures down approximately 100 points [1] - Block, Inc. reported disappointing third-quarter results, with earnings of 54 cents per share, missing the consensus estimate of 67 cents, and revenue of $6.11 billion, below the expected $6.312 billion [1] Company-Specific Summaries - Block, Inc. shares fell 14.4% to $60.75 in pre-market trading following the earnings report [2] - Treace Medical Concepts, Inc. shares dropped 36.4% to $3.96 after cutting FY25 sales guidance below estimates [4] - AirSculpt Technologies, Inc. saw a decline of 28.6% to $7.48 due to disappointing quarterly results [4] - Intellia Therapeutics, Inc. shares tumbled 27.5% to $8.89 after reporting weak quarterly sales [4] - Fox Factory Holding Corp. fell 26.2% to $16.21 after worse-than-expected third-quarter results and lowered fourth-quarter guidance [4] - Power Solutions International, Inc. shares decreased by 22.5% to $63.00 following third-quarter results [4] - Opendoor Technologies Inc. declined 22.5% to $5.05 after reporting third-quarter results [4] - Universal Display Corporation fell 15.4% to $114.50 due to weak quarterly results [4] - Archer Aviation Inc. shares declined 11.4% to $7.85 after announcing the acquisition of Hawthorne Airport [4] - DraftKings Inc. fell 8% to $25.77 after reporting worse-than-expected third-quarter sales and cutting FY25 sales guidance [4]

Core Insights - U.S. stock futures are lower, with Nasdaq futures down approximately 100 points [1] - Block, Inc. reported disappointing third-quarter results, with earnings of 54 cents per share, missing the consensus estimate of 67 cents, and revenue of $6.11 billion, below the expected $6.312 billion [1] Company-Specific Summaries - Block, Inc. shares fell 14.4% to $60.75 in pre-market trading following the earnings report [2] - Treace Medical Concepts, Inc. shares dropped 36.4% to $3.96 after cutting FY25 sales guidance below estimates [4] - AirSculpt Technologies, Inc. saw a decline of 28.6% to $7.48 after posting disappointing quarterly results [4] - Intellia Therapeutics, Inc. tumbled 27.5% to $8.89 due to weak quarterly sales [4] - Fox Factory Holding Corp. fell 26.2% to $16.21 after reporting worse-than-expected results and issuing below-estimate fourth-quarter guidance [4] - Power Solutions International, Inc. shares decreased by 22.5% to $63.00 following third-quarter results [4] - Opendoor Technologies Inc. declined 22.5% to $5.05 after reporting third-quarter results [4] - Universal Display Corporation fell 15.4% to $114.50 due to weak quarterly results [4] - Archer Aviation Inc. declined 11.4% to $7.85 after announcing the acquisition of Hawthorne Airport [4] - DraftKings Inc. shares fell 8% to $25.77 after reporting worse-than-expected sales results and cutting FY25 sales guidance [4]

Core Viewpoint - Xperi reported quarterly earnings of $0.28 per share, exceeding the Zacks Consensus Estimate of $0.25 per share, but down from $0.51 per share a year ago, indicating a mixed performance in earnings despite a positive surprise this quarter [1][2]. Financial Performance - The company achieved revenues of $111.63 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.02%, but down from $132.89 million year-over-year [2]. - Over the last four quarters, Xperi has surpassed consensus EPS estimates three times, but has only topped revenue estimates once [2]. Stock Performance - Xperi shares have declined approximately 38% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [3]. - The stock currently holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the market in the near future [6]. Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.32 on revenues of $117.4 million, and for the current fiscal year, it is $0.84 on revenues of $447.87 million [7]. - The outlook for the Technology Services industry, where Xperi operates, is relatively strong, ranking in the top 39% of over 250 Zacks industries, indicating potential for better performance compared to lower-ranked industries [8].

Core Viewpoint - AirSculpt Technologies (AIRS) is experiencing significant stock performance, with a recent surge in value and strong technical indicators suggesting continued momentum [2][6]. Company Overview - AirSculpt Technologies is valued at $639 million and specializes in body contouring procedures under the Elite Body Sculpture brand, utilizing a proprietary AirSculpt method for minimally invasive fat removal [1]. - The company has achieved a three-year high stock price of $10.80 as of October 22 [4]. Stock Performance - AIRS shares have increased nearly 100% over the past year and approximately 50% in the last month [6]. - Since the Trend Seeker issued a "Buy" signal on September 23, the stock has gained 48.82% [2]. - The stock recently traded at $10.24, with a 50-day moving average of $7.38 [7]. Technical Indicators - AIRS has a 100% "Buy" opinion from Barchart, supported by a Weighted Alpha of +90.50 and a Relative Strength Index (RSI) of 66.60 [7]. - The stock has made 14 new highs and gained 46.06% in the last month [7]. - A technical support level is identified around $9.72 [7]. Financial Projections - Revenue is projected to decline by 9.63% this year but is expected to grow by 5.34% next year [7]. - Earnings are estimated to decrease by 200% this year but are forecasted to increase by 300% next year [7].

Financial Data and Key Metrics Changes - For Q4 2024, revenue totaled $39.2 million, a decline of 17.7% from Q4 2023, with case volume down 16.7% year-over-year [13][33] - Adjusted EBITDA was $1.9 million or 4.7% of revenue, compared to $10.1 million or 21.2% of revenue in the same quarter last year [16][38] - For the full year, revenues were $180.4 million, a decline of 7.9% from fiscal 2023, with adjusted EBITDA of $20.7 million and an adjusted EBITDA margin of 11.5% [18][39] Business Line Data and Key Metrics Changes - Same-store revenue declined 22.6% year-over-year in Q4 2024, reflecting challenges in the aesthetics market [13][33] - The percentage of patients using financing for procedures was 50%, down from 53% in previous quarters [34] Market Data and Key Metrics Changes - The company operates in a $11 billion total addressable market in the U.S. [11] - The consumer backdrop remains challenging, impacting sales across the aesthetics space [14] Company Strategy and Development Direction - The company aims to enhance its culture and align on a singular vision while improving its go-to-market strategy to drive consistent revenue growth [20] - Five key priorities include marketing to drive consumer interest, sales to convert leads, new services to tap into demand, customer experience improvements, and technology enhancements [20][28] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that Q4 2024 was a challenging period but remains confident in the strategy to restore growth and profitability [44] - The company expects Q1 same-store revenue performance to mirror Q4 2024 trends, with sequential improvement anticipated as marketing spend increases [30][42] Other Important Information - The company has paused new center openings to focus on improving same-center performance [29] - A revised credit agreement enhances the company's ability to invest in the business during the transformation [31][41] Q&A Session Summary Question: Can you provide more color on sequential growth expectations? - Management expects to see a similar seasonal trend with sequential improvement in same-store performance year-over-year, anticipating Q2 to be higher than Q1 [51] Question: What are the liquidity improvement actions being taken? - The company drew down on its revolving credit facility to maintain marketing efforts while facing challenges in Q4 results [56] Question: Can you elaborate on the marketing spend versus customer acquisition cost (CAC)? - The elevated CAC was driven by lower case volumes and reduced lead volumes due to decreased marketing spend [62] Question: What is the status of the cost savings program? - The company has executed a $3 million annual savings plan primarily from corporate headcount reductions, with benefits expected to start in Q1 [67] Question: Can you provide specifics on new marketing efforts? - The company is utilizing a combination of paid search and social marketing, with a focus on returns-based approaches and testing new channels like online video [72] Question: What are the plans for new services, particularly skin tightening? - The company plans to pilot skin tightening as a standalone service, capitalizing on consumer interest and trends [76]